Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America

Simple item page
dc.contributor.authorJudith Steinberg
dc.contributor.authorYára Dadalti Fragoso
dc.contributor.authorJuan Carlos Quiroz
dc.contributor.authorJuan Raul García
dc.contributor.authorCaroline Guerra
dc.contributor.authorVirginia Jiménez Rodríguez
dc.contributor.authorClaudia Rodríguez
dc.contributor.authorEthel Ciampi
dc.contributor.authorEdgar Patricio Correa‐Díaz
dc.contributor.authorMiguel Ángel Macías-Rodríguez
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:20:08Z
dc.date.available2026-03-22T14:20:08Z
dc.date.issued2019
dc.descriptionCitaciones: 12
dc.identifier.doi10.1007/s40120-019-0139-y
dc.identifier.urihttps://doi.org/10.1007/s40120-019-0139-y
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/45912
dc.language.isoen
dc.publisherAdis, Springer Healthcare
dc.relation.ispartofNeurology and Therapy
dc.sourceHospital Británico de Buenos Aires
dc.subjectBiosimilar
dc.subjectPharmacovigilance
dc.subjectLatin Americans
dc.subjectMedicine
dc.subjectQuality (philosophy)
dc.subjectRisk analysis (engineering)
dc.subjectBusiness
dc.titlePractical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America
dc.typearticle

Files

Collections

Artículo Científico Publicado